Sichuan Anaerobio Technology

Anaerobio is a clinical-stage biotechnology company based in Chengdu, China, specializing in the development of live biotherapeutic products (LBPs). The company leverages its proprietary anaerobic microorganism technology platform to discover and develop microbial-based therapies for a variety of conditions, including gastrointestinal diseases, metabolic disorders, and oncology. Its lead candidate, KAL-001, is a defined microbial consortium currently in Phase 2 clinical trials for the treatment of recurrent Clostridioides difficile infection. Anaerobio was the first company in China to receive IND approval for an LBP, positioning it as a leader in the domestic microbiome sector. The company's integrated capabilities span from strain isolation and screening to GMP-compliant manufacturing.